In 2014, German researchers Michael Meisterernst and Michael C. Frühwald first reported the anti-tumor effects of ATO in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed GLI1 (8). The gene discussed is GLI1; the disease is rhabdoid tumor.